Vivos therapeutics reports second quarter 2024 financial results and provides operational update

Revenue increased 19% both sequentially and year over year operating expenses decreased 31%, marking eight consecutive quarters of year over year improvement due to successful cost cutting initiatives management to host conference call today at 5:00 pm et littleton, colo., aug. 14, 2024 (globe newswire) -- vivos therapeutics, inc. (“vivos” or the “company'') (nasdaq: vvos), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (osa) in adults), today reported financial results and operating highlights for the second quarter and six months ended june 30, 2024.
VVOS Ratings Summary
VVOS Quant Ranking